GSK Considers HIV-biz Spinoff

Source: Reuters

Oct 23, 2014

GlaxoSmithKline is considering spining of ViiV Healthcare, its fast-growing HIV drugs business, shared with Pfizer and Shionogi.

GSK has a stake of nearly 80 percent in ViiV, with Pfizer and Shionogi holding the rest. Analysts have valued the division at $27 billion.

GSK said the ViiV is considering an IPO in which investors would get a minority stake. Facing drug pipeline issues and China scandal, GSK CEO Andrew Witty said the decision to explore an IPO of a minority shareholding in ViiV Healthcare showed the company's financial flexibility.

In other streamlining efforts, GSK recently announced that it is seeking binding bids by next month for a portfolio of mature drugs worth more than $3 billion, marketed in North America and western Europe.

Read the Reuters press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments